U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137494) titled 'A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)' on Aug. 15.
Brief Summary: This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Study Start Date: Aug. 14
Study Type: INTERVENTIONAL
Condition:
Primary Central Nervous System (CNS) Lymphoma
Secondary Central Nervous System Lymphoma
Intervention:
BIOLOGICAL: MB-CART19.1 Cellular Therapy
MB-CART19.1 will be infused as a single infusion duri...